Subtopic Deep Dive

DNA Topoisomerase I Inhibitors
Research Guide

What is DNA Topoisomerase I Inhibitors?

DNA Topoisomerase I inhibitors are anticancer agents like topotecan and irinotecan that stabilize the covalent topoisomerase I-DNA cleavage complex, preventing DNA religation and inducing lethal DNA damage.

Camptothecin analogs such as topotecan and irinotecan target human topoisomerase I, forming a ternary complex with DNA that blocks replication fork progression (Staker et al., 2002, 795 citations). Irinotecan requires metabolic activation to SN-38, whose glucuronidation by UGT1A1 varies genetically, affecting toxicity (Iyer et al., 1998, 677 citations). Over 10 key papers document mechanisms, resistance, and pharmacokinetics in cancer therapy.

Curated Papers

Key Challenges

Why It Matters

Topoisomerase I inhibitors like irinotecan serve as frontline therapies for colorectal cancer, with outcomes limited by UGT1A1 polymorphisms causing severe diarrhea (Iyer et al., 1998). Resistance via topoisomerase mutations or efflux pumps reduces efficacy in lung and ovarian cancers (Longley and Johnston, 2005; Bukowski et al., 2020). Nanocarrier delivery enhances tumor targeting and overcomes resistance (Pérez-Herrero and Fernández-Medarde, 2015). These advances improve survival rates in metastatic disease.

Key Research Challenges

Acquired Drug Resistance

Tumors develop resistance to topotecan and irinotecan through topoisomerase I mutations or enhanced DNA repair, limiting long-term efficacy (Longley and Johnston, 2005, 1627 citations). Efflux pumps and altered pharmacokinetics exacerbate this issue (Bukowski et al., 2020). Strategies to resensitize cells remain underdeveloped.

Pharmacogenetic Toxicity

UGT1A1*28 polymorphism impairs SN-38 glucuronidation from irinotecan, causing dose-limiting neutropenia and diarrhea (Iyer et al., 1998, 677 citations). Genotyping guides dosing but adoption varies clinically. Personalized dosing protocols need refinement.

Replication Fork Collapse

Topoisomerase I poisoning reverses replication forks via Rad51, leading to DNA breaks unless resolved (Zellweger et al., 2015, 672 citations). Balancing cytotoxicity with fork protection challenges combination therapies. Fork reversal inhibitors could enhance efficacy.

Essential Papers

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Edgar Pérez‐Herrero, Alberto Fernández‐Medarde · 2015 · European Journal of Pharmaceutics and Biopharmaceutics · 1.8K citations

Mechanisms of Multidrug Resistance in Cancer Chemotherapy

Karol Bukowski, Mateusz Kciuk, Renata Kontek · 2020 · International Journal of Molecular Sciences · 1.6K citations

Cancer is one of the main causes of death worldwide. Despite the significant development of methods of cancer healing during the past decades, chemotherapy still remains the main method for cancer ...

Molecular mechanisms of drug resistance

DB Longley, PG Johnston · 2005 · The Journal of Pathology · 1.6K citations

Abstract Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment. Acqui...

Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance

Shiri Navon‐Venezia, Kira Kondratyeva, Alessandra Carattoli · 2017 · FEMS Microbiology Reviews · 1.2K citations

Klebsiella pneumoniae is an important multidrug-resistant (MDR) pathogen affecting humans and a major source for hospital infections associated with high morbidity and mortality due to limited trea...

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Ruixue Huang, Ping‐Kun Zhou · 2020 · Signal Transduction and Targeted Therapy · 1.1K citations

Abstract Radiotherapy is one of the most common countermeasures for treating a wide range of tumors. However, the radioresistance of cancer cells is still a major limitation for radiotherapy applic...

The mechanism of topoisomerase I poisoning by a camptothecin analog

Bart L. Staker, Kathryn A. Hjerrild, M.D. Feese et al. · 2002 · Proceedings of the National Academy of Sciences · 795 citations

We report the x-ray crystal structure of human topoisomerase I covalently joined to double-stranded DNA and bound to the clinically approved anticancer agent Topotecan. Topotecan mimics a DNA base ...

Systems biology of cisplatin resistance: past, present and future

Lorenzo Galluzzi, Ilio Vitale, Judith Michels et al. · 2014 · Cell Death and Disease · 757 citations

Reading Guide

Foundational Papers

Start with Staker et al. (2002) for atomic mechanism of Topotecan poisoning; Iyer et al. (1998) for irinotecan pharmacokinetics; Longley and Johnston (2005) for broad resistance context.

Recent Advances

Bukowski et al. (2020, 1646 citations) updates multidrug resistance; Zellweger et al. (2015) details fork reversal; Pérez-Herrero and Fernández-Medarde (2015) covers nanocarrier enhancements.

Core Methods

Crystal structures (Staker et al., 2002); glucuronidation assays (Iyer et al., 1998); fork progression via DNA combing (Zellweger et al., 2015); efflux pump expression qPCR (Bukowski et al., 2020).

How PapersFlow Helps You Research DNA Topoisomerase I Inhibitors

Discover & Search

Research Agent uses citationGraph on Staker et al. (2002) to map 795-cited structural studies of topotecan-topoisomerase I complexes, revealing clusters on camptothecin analogs. exaSearch queries 'irinotecan resistance UGT1A1' to find Iyer et al. (1998) and similar pharmacokinetics papers. findSimilarPapers expands from Bukowski et al. (2020) to multidrug resistance mechanisms.

Analyze & Verify

Analysis Agent applies readPaperContent to extract Topotecan intercalation details from Staker et al. (2002), then verifyResponse with CoVe checks claims against Longley and Johnston (2005). runPythonAnalysis parses UGT1A1 genotype data from Iyer et al. (1998) for survival correlations using pandas. GRADE grading scores evidence strength for resistance mechanisms in Bukowski et al. (2020).

Synthesize & Write

Synthesis Agent detects gaps in irinotecan resistance literature between Bukowski et al. (2020) and Iyer et al. (1998), flagging unmet needs in combination therapies. Writing Agent uses latexEditText to draft mechanism sections, latexSyncCitations for 10+ references, and latexCompile for publication-ready reviews. exportMermaid visualizes topoisomerase I poisoning pathways from Staker et al. (2002).

Use Cases

"Extract dose-response data from irinotecan UGT1A1 papers and plot SN-38 glucuronidation rates"

Research Agent → searchPapers('irinotecan UGT1A1') → Analysis Agent → readPaperContent(Iyer 1998) → runPythonAnalysis(pandas plot AUC vs genotype) → matplotlib survival curves output.

"Write LaTeX review on topotecan mechanism with citations and fork reversal diagram"

Synthesis Agent → gap detection(Staker 2002 + Zellweger 2015) → Writing Agent → latexEditText(structure) → latexSyncCitations(10 papers) → exportMermaid(fork diagram) → latexCompile(PDF output).

"Find GitHub repos analyzing topoisomerase inhibitor simulations"

Research Agent → searchPapers('topoisomerase I molecular dynamics') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(DNA docking scripts) → runPythonAnalysis(reproduce binding affinities).

Automated Workflows

Deep Research workflow scans 50+ papers via searchPapers on 'topoisomerase I inhibitors cancer', chains citationGraph to Longley (2005), and outputs structured report on resistance mechanisms. DeepScan applies 7-step analysis: readPaperContent(Iyer 1998), CoVe verify UGT1A1 claims, runPythonAnalysis on pharmacokinetics. Theorizer generates hypotheses linking Staker (2002) structures to nanocarrier designs from Pérez-Herrero (2015).

Try Doxa for DNA Topoisomerase I Inhibitors Research

Frequently Asked Questions

What defines DNA Topoisomerase I inhibitors?

Agents like topotecan and irinotecan stabilize the topoisomerase I-DNA cleavage complex, blocking religation and causing replication fork collapse (Staker et al., 2002).

What are key methods in this field?

X-ray crystallography reveals Topotecan binding (Staker et al., 2002); liver microsome assays measure SN-38 glucuronidation by UGT1A1 (Iyer et al., 1998); cell line studies track resistance via efflux and mutations (Bukowski et al., 2020).

What are seminal papers?

Staker et al. (2002, 795 citations) details Topotecan poisoning mechanism; Iyer et al. (1998, 677 citations) links UGT1A1 to irinotecan toxicity; Longley and Johnston (2005, 1627 citations) reviews resistance pathways.

What open problems exist?

Overcoming UGT1A1-limited dosing for irinotecan (Iyer et al., 1998); reversing fork protection in resistant cells (Zellweger et al., 2015); integrating nanocarriers to bypass efflux (Pérez-Herrero and Fernández-Medarde, 2015).